RECURRENCE RATES FOLLOWING TESTOSTERONE THERAPY IN A LARGE CLINICAL COHORT OF MEN WITH PROSTATE CANCER
There is a limited evidence regarding the safety of testosterone (T) therapy (TTh) in men with a history of prostate cancer (PCa). We present here a large single-center experience of TTh in men after a variety of PCa treatments to help guide further clinical decision-making.
The electronic medical record database at a men's health center affiliated with an academic hospital was queried to identify men who received TTh for testosterone deficiency after diagnosis and/or treatment of PCa over the previous 5y. Testosterone was delivered via transdermal gels/liquids, short- and long-acting injections, and/or pellets. Biochemical recurrence (BCR) was operationally defined as PSA 0.3 ng/ml or higher after radical prostatectomy (RP), and PSA nadir plus 2 ng/ml after primary radiation treatment (external beam, brachytherapy). For men on active surveillance (AS) progression was defined as any biopsy showing higher Gleason score than initial diagnosis.
We identified 320 men with a diagnosis of both PCa and T deficiency. Of these, 222 men received TTh. We excluded from analysis men with